Projects funded by the NCN
Dual CBR1-AKR1C3 inhibitors as a new approach to improve effectiveness and safety of anthracycline therapy.
2020/37/N/NZ7/01097
Keywords:
CBR1 AKR1C3 anthracyclines chemiotherapy cancer cardiotoxicity drug resistance
Descriptors:
- NZ7_14: Pharmacy, pharmacotherapy, pharmacology
- NZ4_11: Metabolism
- NZ5_7: Human disease treatment
Panel:
NZ7 - Diagnostic tools, therapies and public health: public health, epidemiology, environmental health risks and occupational medicine, medical ethics, drug discovery and therapies, pharmacology
Host institution :
Uniwersytet Jagielloński, Collegium Medicum
woj. małopolskie
Principal investigator (from the host institution):
Number of co-investigators in the project: 3
Call: PRELUDIUM 19 - announced on 2020-03-16
Amount awarded: 139 980 PLN
Project start date (Y-m-d): 2021-01-19
Project end date (Y-m-d): 2023-01-18
Project duration:: 24 months (the same as in the proposal)
Project status: Project settled
Project description
Download the project description in a pdf file
Note - project descriptions were prepared by the authors of the applications themselves and placed in the system in an unchanged form.